Trials / Completed
CompletedNCT00415571
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- QuatRx Pharmaceuticals Company · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fispemifene (once daily for 8 weeks) |
Timeline
- Start date
- 2006-12-01
- Completion
- 2008-08-01
- First posted
- 2006-12-25
- Last updated
- 2010-02-03
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00415571. Inclusion in this directory is not an endorsement.